Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future

Karlyne M. Reilly, Ae Rang Kim, Jaishri Blakely, Rosalie E. Ferner, David H. Gutmann, Eric Legius, Markku M. Miettinen, R Randall, Nancy Ratner, N. L. Jumbé, Annette Bakker, David Viskochil, Brigitte C. Widemann, Douglas R. Stewart

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled "MPNST State of the Science: Outlining a Research Agenda for the Future" was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.

Original languageEnglish (US)
JournalJournal of the National Cancer Institute
Volume109
Issue number8
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Neurofibromatosis 1
Neurilemmoma
Research
Plexiform Neurofibroma
Information Dissemination
Drug Resistance
Sarcoma
Positron-Emission Tomography
Therapeutics
Magnetic Resonance Imaging
Databases
Guidelines
Neoplasm Metastasis
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reilly, K. M., Kim, A. R., Blakely, J., Ferner, R. E., Gutmann, D. H., Legius, E., ... Stewart, D. R. (2017). Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. Journal of the National Cancer Institute, 109(8). https://doi.org/10.1093/jnci/djx124

Neurofibromatosis Type 1-Associated MPNST State of the Science : Outlining a Research Agenda for the Future. / Reilly, Karlyne M.; Kim, Ae Rang; Blakely, Jaishri; Ferner, Rosalie E.; Gutmann, David H.; Legius, Eric; Miettinen, Markku M.; Randall, R; Ratner, Nancy; Jumbé, N. L.; Bakker, Annette; Viskochil, David; Widemann, Brigitte C.; Stewart, Douglas R.

In: Journal of the National Cancer Institute, Vol. 109, No. 8, 01.08.2017.

Research output: Contribution to journalReview article

Reilly, KM, Kim, AR, Blakely, J, Ferner, RE, Gutmann, DH, Legius, E, Miettinen, MM, Randall, R, Ratner, N, Jumbé, NL, Bakker, A, Viskochil, D, Widemann, BC & Stewart, DR 2017, 'Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future', Journal of the National Cancer Institute, vol. 109, no. 8. https://doi.org/10.1093/jnci/djx124
Reilly, Karlyne M. ; Kim, Ae Rang ; Blakely, Jaishri ; Ferner, Rosalie E. ; Gutmann, David H. ; Legius, Eric ; Miettinen, Markku M. ; Randall, R ; Ratner, Nancy ; Jumbé, N. L. ; Bakker, Annette ; Viskochil, David ; Widemann, Brigitte C. ; Stewart, Douglas R. / Neurofibromatosis Type 1-Associated MPNST State of the Science : Outlining a Research Agenda for the Future. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 8.
@article{b11b7df38acb4405b64e2687bfeeb1f3,
title = "Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future",
abstract = "Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled {"}MPNST State of the Science: Outlining a Research Agenda for the Future{"} was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.",
author = "Reilly, {Karlyne M.} and Kim, {Ae Rang} and Jaishri Blakely and Ferner, {Rosalie E.} and Gutmann, {David H.} and Eric Legius and Miettinen, {Markku M.} and R Randall and Nancy Ratner and Jumb{\'e}, {N. L.} and Annette Bakker and David Viskochil and Widemann, {Brigitte C.} and Stewart, {Douglas R.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1093/jnci/djx124",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Neurofibromatosis Type 1-Associated MPNST State of the Science

T2 - Outlining a Research Agenda for the Future

AU - Reilly, Karlyne M.

AU - Kim, Ae Rang

AU - Blakely, Jaishri

AU - Ferner, Rosalie E.

AU - Gutmann, David H.

AU - Legius, Eric

AU - Miettinen, Markku M.

AU - Randall, R

AU - Ratner, Nancy

AU - Jumbé, N. L.

AU - Bakker, Annette

AU - Viskochil, David

AU - Widemann, Brigitte C.

AU - Stewart, Douglas R.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled "MPNST State of the Science: Outlining a Research Agenda for the Future" was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.

AB - Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled "MPNST State of the Science: Outlining a Research Agenda for the Future" was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.

UR - http://www.scopus.com/inward/record.url?scp=85037681578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037681578&partnerID=8YFLogxK

U2 - 10.1093/jnci/djx124

DO - 10.1093/jnci/djx124

M3 - Review article

C2 - 29117388

AN - SCOPUS:85037681578

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

ER -